title: Boron chemicals in diagnosis and therapeutics.
abstract: Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade(®)), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.
authors.affiliation: Division of Hematology & Oncology, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS 66103, USA. bdas@kumc.edu
authors.forename: Bhaskar C
authors.initials: BC
authors.lastname: Das
authors.forename: Pritam
authors.initials: P
authors.lastname: Thapa
authors.forename: Radha
authors.initials: R
authors.lastname: Karki
authors.forename: Caroline
authors.initials: C
authors.lastname: Schinke
authors.forename: Sasmita
authors.initials: S
authors.lastname: Das
authors.forename: Suman
authors.initials: S
authors.lastname: Kambhampati
authors.forename: Sushanta K
authors.initials: SK
authors.lastname: Banerjee
authors.forename: Peter
authors.initials: P
authors.lastname: Van Veldhuizen
authors.forename: Amit
authors.initials: A
authors.lastname: Verma
authors.forename: Louis M
authors.initials: LM
authors.lastname: Weiss
authors.forename: Todd
authors.initials: T
authors.lastname: Evans
mesh_terms: D001896:Boron Compounds / Q000737:chemistry* / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy; D001897:Boronic Acids / Q000737:chemistry / Q000627:therapeutic use; D000069286:Bortezomib; D005456:Fluorescent Dyes / Q000737:chemistry; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry / Q000378:metabolism; D061988:Proteasome Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D011719:Pyrazines / Q000737:chemistry / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000737:chemistry
chemical_list: C095489:4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; D001896:Boron Compounds; D001897:Boronic Acids; D005456:Fluorescent Dyes; D061988:Proteasome Inhibitors; D011719:Pyrazines; D017382:Reactive Oxygen Species; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex